Topical glaucoma medications – Clinical implications for the ocular surface
Peer reviewed, Journal article
MetadataShow full item record
Original versionFineide, F., Lagali, N., Adil, M. Y., Arita, R., Kolko, M., Vehof, J., & Utheim, T. P. (2022). Topical glaucoma medications–Clinical implications for the ocular surface. The ocular surface, 26 19-49. 10.1016/j.jtos.2022.07.007
Glaucoma is a leading cause of irreversible blindness. The use of topical eye drops to reduce intraocular pressure remains the mainstay treatment. These eye drops frequently contain preservatives designed to ensure sterility of the compound. A growing number of clinical and experimental studies report the detrimental effects of not only these preservatives but also the active pharmaceutical compounds on the ocular surface, with resultant tear film instability and dry eye disease. Herein, we critically appraise the published literature exploring the effects of preservatives and pharmaceutical compounds on the ocular surface.